NetworkNewsBreaks – Cellectar Biosciences Inc. (NASDAQ: CLRB) Secures $45M in Underwritten Public Offering and Concurrent Private Placement
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has completed an underwritten public offering and concurrent private placement. According to the update, Cellectar sold 18,148,136 shares of its common stock as part of the underwritten public offering. Each of the shares were sold at the public offering price of $1.35, resulting in approximately $24.5 million in gross proceeds. In addition, Cellectar Biosciences secured approximately $20.5 million in gross proceeds from the concurrent private placement, with the offering led by healthcare-focused institutional investors. Roth Capital Partners…







